Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic Implications of the Residual Tumor Microenvironment after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients without Pathological Complete Response.
Lejeune M, Reverté L, Sauras E, Gallardo N, Bosch R, Roso A, Petit A, Peg V, Riu F, García-Fontgivell J, Ibáñez J, Relea F, Vieites B, Bor C, de la Cruz-Merino L, Arenas M, Rodriguez V, Galera J, Korzynska A, Belhomme P, Plancoulaine B, Álvaro T, López C. Lejeune M, et al. Cancers (Basel). 2023 Jan 18;15(3):597. doi: 10.3390/cancers15030597. Cancers (Basel). 2023. PMID: 36765559 Free PMC article.
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
Long GV, Luke JJ, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, Mohr P, Dummer R, Gershenwald JE, Yoon CH, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Ascierto PA; KEYNOTE-716 Investigators. Long GV, et al. Lancet Oncol. 2022 Nov;23(11):1378-1388. doi: 10.1016/S1470-2045(22)00559-9. Epub 2022 Oct 18. Lancet Oncol. 2022. PMID: 36265502 Clinical Trial.
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Ascierto PA, Del Vecchio M, Mandalá M, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob JJ, Chiarion-Sileni V, Márquez-Rodas I, Butler MO, Maio M, Middleton MR, de la Cruz-Merino L, Arenberger P, Atkinson V, Hill A, Fecher LA, Millward M, Khushalani NI, Queirolo P, Lobo M, de Pril V, Loffredo J, Larkin J, Weber J. Ascierto PA, et al. Lancet Oncol. 2020 Nov;21(11):1465-1477. doi: 10.1016/S1470-2045(20)30494-0. Epub 2020 Sep 19. Lancet Oncol. 2020. PMID: 32961119 Clinical Trial.
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival.
Mandala M, Larkin J, Ascierto PA, Del Vecchio M, Gogas H, Cowey CL, Arance A, Dalle S, Schenker M, Grob JJ, Chiarion-Sileni V, Marquez-Rodas I, Butler MO, Di Giacomo AM, Lutzky J, De La Cruz-Merino L, Atkinson V, Arenberger P, Hill A, Fecher L, Millward M, Khushalani NI, de Pril V, Lobo M, Weber J. Mandala M, et al. J Immunother Cancer. 2021 Aug;9(8):e003188. doi: 10.1136/jitc-2021-003188. J Immunother Cancer. 2021. PMID: 34452930 Free PMC article.
MULTI-CRITERIA DECISION ANALYSIS AS A DECISION-SUPPORT TOOL FOR DRUG EVALUATION: A PILOT STUDY IN A PHARMACY AND THERAPEUTICS COMMITTEE SETTING.
Roldán ÚB, Badia X, Marcos-Rodríguez JA, de la Cruz-Merino L, Gómez-González J, Melcón-de Dios A, Caraballo-Camacho MO, Cordero-Ramos J, Alvarado-Fernández MD, Galiana-Auchel JM, Calleja-Hernández MÁ. Roldán ÚB, et al. Int J Technol Assess Health Care. 2018 Jan;34(5):519-526. doi: 10.1017/S0266462318000569. Epub 2018 Oct 23. Int J Technol Assess Health Care. 2018. PMID: 30348241
Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group.
Rueda A, Calvo V, Casanova M, Rodriguez-Abreu D, Aguiar D, Llanos M, Alvarez R, Martinez-Banaclocha N, Alfaro J, Quero C, Blasco A, de la Cruz Merino L, Herrero J, García-Arroyo FR, Provencio M. Rueda A, et al. Leuk Lymphoma. 2019 Jun;60(6):1576-1579. doi: 10.1080/10428194.2018.1542147. Epub 2018 Dec 5. Leuk Lymphoma. 2019. PMID: 30516082 Clinical Trial. No abstract available.
SEOM clinical guideline for the management of cutaneous melanoma (2020).
Majem M, Manzano JL, Marquez-Rodas I, Mujika K, Muñoz-Couselo E, Pérez-Ruiz E, de la Cruz-Merino L, Espinosa E, Gonzalez-Cao M, Berrocal A. Majem M, et al. Clin Transl Oncol. 2021 May;23(5):948-960. doi: 10.1007/s12094-020-02539-9. Epub 2021 Mar 2. Clin Transl Oncol. 2021. PMID: 33651321 Free PMC article.
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.
Larkin J, Weber J, Del Vecchio M, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob JJ, Chiarion-Sileni V, Márquez-Rodas I, Butler MO, Di Giacomo AM, Middleton MR, De la Cruz-Merino L, Arenberger P, Atkinson V, Hill A, Fecher LA, Millward M, Khushalani NI, Queirolo P, Long GV, Lobo M, Askelson M, Ascierto PA, Mandalá M. Larkin J, et al. Eur J Cancer. 2022 Sep;173:285-296. doi: 10.1016/j.ejca.2022.06.041. Epub 2022 Aug 11. Eur J Cancer. 2022. PMID: 35964471 Free article. Clinical Trial.
118 results